Genomic Health (GHDX) - Get Genomic Health, Inc. Report was upgraded to buy from hold at Canaccord Genuity. $44 price target. Survey suggests the company's prostate test will lead to growth, Canaccord said.
Hyatt (H) - Get Hyatt Hotels Corporation Class A Report was downgraded to neutral from overweight at JPMorgan. $50 price target. Analysts see less upside potential to earnings estimates, JPMorgan said.
HCA (HCA) - Get HCA Healthcare Inc (HCA) Report was downgraded to market perform at Leerink Partners. $74 price target. Fundamentals are weak, given headwinds from the Affordable Care Act, Leerink said.
Lockheed Martin (LMT) - Get Lockheed Martin Corporation (LMT) Report was upgraded to outperform from sector perform at RBC Capital Markets. $250 price target. The company is most levered to rising defense spending, RBC said.
Qlik (QLIK) was downgraded to sector weight at Pacific Crest. Consensus expectations appear too optimistic, Pacific Crest said.
Smith & Wesson (SWHC) was downgraded to neutral from outperform at Wedbush Securities. The valuation looks less attractive, based on a $26 price target, Wedbush said.
Tyco (TYC) was downgraded to sector perform from outperform at RBC Capital Markets. $34 price target. The company has high cyclical exposure, said RBC.
United Technologies undefined was downgraded to neutral from buy at Sterne Agee. $100 price target. The company lacks near-term catalysts, Sterne Agee said.
This article was written by a staff member of TheStreet.